Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2024

Conditions

Relapsed or Refractory DLBCL

Interventions

DRUG

Anti-PD-1 Antibody Plus Chidamide and Rituximab

Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks